Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 13/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10297431 | 1.00 | KMT2A (0.45) | KMT2AMEN1CMA1ACEELANE | |
| SCHEMBL17029374 | 1.00 | KMT2A (0.45) | KMT2AMEN1CMA1ACEELANE | |
| SCHEMBL10297422 | 0.96 | KMT2A (0.47) | KMT2AMEN1CMA1ACEELANE | |
| SCHEMBL10297467 | 0.96 | KMT2A (0.47) | KMT2AMEN1CMA1ACEELANE | |
| SCHEMBL10297454 | 0.87 | CMA1 (0.49) | KMT2AMEN1CMA1ELANE | |
| SCHEMBL17029373 | 0.87 | CMA1 (0.49) | KMT2AMEN1CMA1ELANE | |
| SCHEMBL10297416 | 0.87 | CMA1 (0.49) | KMT2AMEN1CMA1ELANE | |
| SCHEMBL10297436 | 0.85 | CMA1 (0.60) | CMA1ACE | |
| SCHEMBL10297461 | 0.85 | CMA1 (0.60) | CMA1ACE | |
| SCHEMBL14479881 | 0.85 | CMA1 (0.60) | CMA1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211637-B2 | Proteinase K inhibitors, methods and compositions therefor | Life Technologies Corporation (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100159482-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | Life Technologies Corporation (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100159482-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | CPSF7, CTSL, CTSK | KMT2A 1951/4885MEN1 3115/4885CMA1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.